This NDC is on FDA's drug shortage list (posted Feb 20, 2018)
Product Information
BUPIVACAINE 0.25% VIAL is a generic product labeled by Somerset Therapeutics, LLC, priced at $0.0479 per ML under NDC 70069075201. Its NADAC has been published 50 times since Oct 22, 2025.
FDA first approved this application on Nov 20, 2023. Its Orange Book therapeutic-equivalence code is AP.
Strength
2.5 mg/mL
Manufacturer
Somerset Therapeutics, LLCNDC
70069075201
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INFILTRATION; PERINEURAL
Effective Date
5/20/2026
Active Ingredients
BUPIVACAINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA217792FDA Approved
11/20/2023
TE Code
AP
On Market Since
11/27/2023
Pharmacological Classes
Price Statistics
The NADAC for BUPIVACAINE 0.25% VIAL has been published 50 times since Oct 22, 2025, and over the history we have for it it has risen 3.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0479 per ML |
|---|---|
| All-time high | $0.0479 (Sep 30, 2026) |
| All-time low | $0.0453 (Nov 19, 2025) |
| 52-week high | $0.0479 |
| 52-week low | $0.0453 |
| Median price | $0.0479 |
| Average price | $0.0472 |
| Largest weekly change | +2.6% (Feb 18, 2026) |
| Weeks tracked | 50 |
| Tracking since | Oct 22, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Bupivacaine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Somerset Therapeutics, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bupivacaine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Amide Local Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPIVACAINE 0.25% VIAL?
The current National Average Drug Acquisition Cost (NADAC) for BUPIVACAINE 0.25% VIAL, manufactured by Somerset Therapeutics, LLC, is $0.0479 per ML (NDC 70069075201), effective Sep 30, 2026.
How has the price of BUPIVACAINE 0.25% VIAL changed over time?
Over the history we have for it, the NADAC for BUPIVACAINE 0.25% VIAL has risen 3.4%. It has been tracked across 50 weekly CMS publications since Oct 22, 2025.
What are the highest and lowest recorded NADAC prices for BUPIVACAINE 0.25% VIAL?
Since Oct 22, 2025, the NADAC for BUPIVACAINE 0.25% VIAL has ranged from a low of $0.0453 (Nov 19, 2025) to a high of $0.0479 (Sep 30, 2026), with a median of $0.0479 per ML.
Are there cheaper alternatives to BUPIVACAINE 0.25% VIAL?
No other NADAC-published product currently shares the active ingredient and strength of BUPIVACAINE 0.25% VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUPIVACAINE 0.25% VIAL?
BUPIVACAINE 0.25% VIAL (NDC 70069075201) is labeled by Somerset Therapeutics, LLC, and CMS classifies it as a generic product.
Is BUPIVACAINE 0.25% VIAL in shortage?
Yes — NDC 70069075201 is currently listed in FDA's drug shortage database (posted Feb 20, 2018).